Next Article in Journal
Tumor-Agnostic Biomarkers: Heed Caution, and Why Cell of Origin Still Matters
Previous Article in Journal
Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review
Article

Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

1
Department of Surgery, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA 30310, USA
2
Biomedical Laboratory Research & Development Service, Department of Veterans Affairs, Office of Research and Development, Birmingham VA Medical Center, 700 19th Street, Birmingham, AL 35233, USA
3
Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA 30310, USA
4
Atlanta VA Medical Center, Atlanta VA Health Care System, 1670 Clairmont Road, Decatur, GA 30033, USA
5
Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, 550 Peachtree Road NE, Atlanta, GA 30308, USA
6
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 E Clifton Rd NE, Building C, Atlanta, GA 30322, USA
7
Ora Lee Smith Cancer Research Foundation, Advanced Technology and Development Center, 75 5th Street NW, Atlanta, GA 30308, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Steven A. Rosenzweig
Onco 2021, 1(2), 83-94; https://doi.org/10.3390/onco1020007
Received: 24 July 2021 / Revised: 11 September 2021 / Accepted: 18 September 2021 / Published: 29 September 2021
Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes. View Full-Text
Keywords: docetaxel; combination therapy; nanoparticles; head and neck squamous cell carcinoma; oncology; therapies docetaxel; combination therapy; nanoparticles; head and neck squamous cell carcinoma; oncology; therapies
Show Figures

Figure 1

MDPI and ACS Style

Lee, G.Y.; Mubasher, M.; McKenzie, T.S.; Schmitt, N.C.; Sebelik, M.E.; Flanagan, C.E.; Osta, B.E.; Cothran, M.B.; Green, H.-N. Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer. Onco 2021, 1, 83-94. https://doi.org/10.3390/onco1020007

AMA Style

Lee GY, Mubasher M, McKenzie TS, Schmitt NC, Sebelik ME, Flanagan CE, Osta BE, Cothran MB, Green H-N. Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer. Onco. 2021; 1(2):83-94. https://doi.org/10.3390/onco1020007

Chicago/Turabian Style

Lee, Gee Y., Mohamed Mubasher, Tamra S. McKenzie, Nicole C. Schmitt, Merry E. Sebelik, Carrie E. Flanagan, Badi E. Osta, Maya B. Cothran, and Hadiyah-Nicole Green. 2021. "Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer" Onco 1, no. 2: 83-94. https://doi.org/10.3390/onco1020007

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop